--- schema_version: "secwatch.filing_event.v1" accession: "0001213900-24-030473" form_type: "8-K" ticker: "ALLR" cik: "0001860657" company_name: "Allarity Therapeutics, Inc." filed_at: "2024-04-04T23:59:59+00:00" generated_at: "2026-06-04T02:28:02.427018+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.65 calibrated_materiality_score: 0.65 confidence: "high" source: SEC EDGAR --- # Allarity Therapeutics approves 1-for-20 reverse stock split effective April 9, 2024 ## Summary - Stockholders approved 1-for-20 reverse stock split at April 1 special meeting; ratio set by Board. - Reverse split effective April 9, 2024 at 9:30 a.m. ET; trading symbol ALLR unchanged; new CUSIP 016744401. - No fractional shares issued; any fractional rounded up to next whole number. Authorized shares unchanged at 750M. - Amendment to 2021 Equity Incentive Plan passed, adding 1,000,000 authorized shares. - Adjournment proposal also passed but not needed as reverse split proposal already approved. ## SEC filing metadata - accession: 0001213900-24-030473 - form_type: 8-K - ticker: ALLR - cik: 0001860657 - company_name: Allarity Therapeutics, Inc. - filed_at: 2024-04-04T23:59:59+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.65 - calibrated_materiality_score: 0.65 - confidence: high - sec_items: 3.03, 5.03, 5.07, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390024030473/0001213900-24-030473-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390024030473/ea0203322-8k_allarity.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001213900-24-030473 - JSON: https://secwatch.observer/filing/0001213900-24-030473.json - Plain text: https://secwatch.observer/filing/0001213900-24-030473.txt ## Key facts - Governance Changes Allarity Therapeutics, Inc.: Filed Fifth Certificate of Amendment to effect a 1-for-20 reverse stock split of common stock (effective 2024-04-09). - Change: charter amendment - Effective: 2024-04-09 source text: On April 4, 2024, Allarity Therapeutics, Inc., a Delaware corporation (the “Company”) filed a Fifth Certificate of Amendment to Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of Delaware to effect a 1-for-20 reverse stock split of the shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), effective as of 9:30 a.m. (Eastern Time) on April 9, 2024 evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390024030473/0001213900-24-030473-index.htm - Shareholder Votes Allarity Therapeutics, Inc. shareholders approved Approve adjournment of special meeting to solicit additional proxies in favor of Reverse Stock Split Proposal. - Proposal: reverse split - Outcome: passed source text: Proposal 3 : To approve the adjournment of the meeting, if necessary or advisable, to solicit additional proxies in favor of the Reverse Stock Split Proposal (the “Adjournment Proposal”). Votes For Votes Against Abstentions Broker Non-Votes 4,598,095 1,130,018 4,143 - evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390024030473/0001213900-24-030473-index.htm - Shareholder Votes Allarity Therapeutics, Inc. shareholders approved Approve amendment to 2021 Equity Incentive Plan to increase authorized shares by 1,000,000. - Proposal: equity plan - Outcome: passed source text: Proposal 1 : To approve an amendment to the Allarity Therapeutics, Inc. 2021 Equity Incentive Plan, a copy of such amended and restated plan is included as Appendix A to the Proxy Statement (the “2021 Plan”), to increase the aggregate number of shares of Common Stock authorized for issuance by 1,000,000 shares (the “Amendment to the 2021 Plan Proposal”). Votes For Votes Against Abstentions Broker Non-Votes 3,898,165 294,784 1,917 1,537,390 evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390024030473/0001213900-24-030473-index.htm - Shareholder Votes Allarity Therapeutics, Inc. shareholders approved Approve amendment to Certificate of Incorporation to effect reverse stock split at ratio between 1:5 and 1:20. - Proposal: reverse split - Outcome: passed source text: Proposal 2 : To approve an amendment to the Allarity Therapeutics, Inc. Certificate of Incorporation, as amended (the “Charter Amendment”), in substantially the form attached to the Proxy Statement as Appendix B, to, at the discretion of the Board of Directors of the Company (the “Board”), effect a reverse stock split with respect to the Company’s issued and outstanding Common Stock, par value $0.0001 per share, at a ratio between 1-for-5 and 1-for-20 (the “Range”), with the ratio within such Range to be determined at the discretion of the Board (the “Reverse Stock Split Proposal”) and included in a public announcement. Votes For Votes Against Abstentions Broker Non-Votes 4,619,400 1,095,954 16,902 - evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390024030473/0001213900-24-030473-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.